Pages that link to "Q38282800"

The following pages link to New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions (Q38282800):

Displaying 30 items.

• Hepatobiliary Tumors: Update on Diagnosis and Management (Q26775654) (← links)
• Vitamin K and hepatocellular carcinoma: The basic and clinic (Q26783713) (← links)
• Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature (Q28067445) (← links)
• Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma (Q29248288) (← links)
• A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. (Q33442349) (← links)
• Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy (Q36269679) (← links)
• A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway (Q36544739) (← links)
• Treatment of Liver Cancer by C/EBPA saRNA. (Q38287891) (← links)
• Cabozantinib in the treatment of hepatocellular carcinoma. (Q38658285) (← links)
• Clinical trials of antiangiogenic therapy for hepatocellular carcinoma (Q38743040) (← links)
• Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro (Q38785187) (← links)
• Promising new strategies for hepatocellular carcinoma (Q38936589) (← links)
• Increased FoxM1 expression is associated with clinicopathological features and confers a poor prognosis in human hepatocellular carcinoma. (Q39077208) (← links)
• Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma. (Q40250784) (← links)
• Fibrinogen and D-dimer levels elevate in advanced hepatocellular carcinoma: High pretreatment fibrinogen levels predict poor outcomes (Q40425505) (← links)
• The role of autophagy in hepatocellular carcinoma: friend or foe. (Q41339988) (← links)
• Oncogenic secretory clusterin in hepatocellular carcinoma: Expression at early staging and emerging molecular target (Q41592701) (← links)
• The multifaceted role of podoplanin expression in hepatocellular carcinoma (Q41866316) (← links)
• Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy (Q42053469) (← links)
• miR-155-5p modulates malignant behaviors of hepatocellular carcinoma by directly targeting CTHRC1 and indirectly regulating GSK-3β-involved Wnt/β-catenin signaling (Q47300446) (← links)
• Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma (Q47869247) (← links)
• Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. (Q50076590) (← links)
• Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. (Q52345488) (← links)
• Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. (Q54977952) (← links)
• INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma (Q64064212) (← links)
• Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling (Q64069143) (← links)
• Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma (Q89861316) (← links)
• Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma (Q91386648) (← links)
• Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma (Q91597640) (← links)
• Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition (Q92013749) (← links)